- Home
- MDP News & Resources
- Videos
- GSK: Supply chain – a critical link in combating neglected tropical diseases
Videos
GSK: Supply chain – a critical link in combating neglected tropical diseases
11 July 2017 | Topics: Albendazole, GSK, LF Elimination, Lymphatic Filariasis, Mectizan, Merck
Related articles
Resources and Tools
Managing Morbidity and Preventing Disability (MMDP) Toolkit
The World Health Organization (WHO) is developing a toolkit to help programs implement MMDP services. The toolkit incorporates relevant resources developed by WHO and partner institutions, and its objectives are as follows:
provide tools and templates for implementation of key activities to strengthen delivery by the health system of the recommended minimum package of care for LF patients make information and tools accessible to national LF programs and health professionals around the world identify and resolve gaps in resourcesComponents focus on the following areas:
Planning, including patient estimation Capacity Building to Deliver MMDP Services Documentation of MMDP servicesScientific Publication
A Success Story from Togo – new PLOS NTDs paper
The Mectizan Donation Program is pleased to share a recently published paper titled: “A Success Story: Togo is Moving Toward Becoming the First Sub-Saharan African Nation to Eliminate Lymphatic Filariasis Through Mass Drug Administration and Countrywide Morbidity Alleviation” by Dr.
journal.pntd_.0002080 (563.14 KB)Report
Report from the 7th Meeting of the GAELF
This report summarizes the 7th meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF), Washington DC, November 18-19, 2012. The theme, “A Future Free of Lymphatic Filariasis: Reaching the Vision by Scaling Up, Scaling Down and Reaching Out”, emphasized new strategies and partnerships necessary to reach the 2020 goal of elimination of lymphatic filariasis (LF) as a public-health problem.
GAELFreport (1.32 MB)WHO Guide
Lymphatic Filariasis: Managing Morbidity and Preventing Disability
Guide on planning, implementing and monitoring activities at national level. This guide provides the best available information on managing morbidity and preventing disability after acute dermatolymphangioadenitis (ADLA; acute attacks), lymphoedema or elephantiasis, and hydrocoele.